We hypothesize that PARG inhibitor can serve as a targeted HNRNPH1 inhibitor for a combination of chemotherapies in CML patients with high level of HNRNPH1, which deserves further exploration. This evidence concerns the gene HNRNPH1 and chronic myelogenous leukemia, BCR-ABL1 positive.